| Literature DB >> 35131834 |
Barbara Seebacher1,2, Birgit Helmlinger3,4, Daniela Pinter3,4, Rainer Ehling2,5, Harald Hegen6, Stefan Ropele3, Gernot Reishofer7, Christian Enzinger8, Christian Brenneis2,5, Florian Deisenhammer6.
Abstract
INTRODUCTION: Motor imagery (MI) refers to the mental rehearsal of a physical action without muscular activity. Our previous studies showed that MI combined with rhythmic-auditory cues improved walking, fatigue and quality of life (QoL) in people with multiple sclerosis (pwMS). Largest improvements were seen after music and verbally cued MI. It is unclear whether actual cued gait training achieves similar effects on walking as cued MI in pwMS. Furthermore, in pwMS it is unknown whether any of these interventions leads to changes in brain activation. The purpose of this study is therefore to compare the effects of imagined and actual cued gait training and a combination thereof on walking, brain activation patterns, fatigue, cognitive and emotional functioning in pwMS. METHODS AND ANALYSIS: A prospective double-blind randomised parallel multicentre trial will be conducted in 132 pwMS with mild to moderate disability. Randomised into three groups, participants will receive music, metronome and verbal cueing, plus MI of walking (1), MI combined with actual gait training (2) or actual gait training (3) for 30 min, 4× per week for 4 weeks. Supported by weekly phone calls, participants will practise at home, guided by recorded instructions. Primary endpoints will be walking speed (Timed 25-Foot Walk) and distance (2 min Walk Test). Secondary endpoints will be brain activation patterns, fatigue, QoL, MI ability, anxiety, depression, cognitive functioning, music-induced motivation-to-move, pleasure, arousal and self-efficacy. Data will be collected at baseline, postintervention and 3-month follow-up. MRI reference values will be generated using 15 matched healthy controls. ETHICS AND DISSEMINATION: This study follows the Standard Protocol Items: Recommendations for Interventional Trials-PRO Extension. Ethical approval was received from the Ethics Committees of the Medical Universities of Innsbruck (1347/2020) and Graz (33-056 ex 20/21), Austria. Results will be disseminated via national and international conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: DRKS00023978. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: multiple sclerosis; neurology; rehabilitation medicine
Mesh:
Year: 2022 PMID: 35131834 PMCID: PMC8823210 DOI: 10.1136/bmjopen-2021-056666
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Eligibility criteria
| People with MS |
Any MS phenotype according to the revised McDonald’s criteria Aged 18 years or older Any ethnicity Disability status score on the Expanded Disability Status Scale (EDSS) Stable disease; no clinical evidence of disease activity Ability to speak and understand German language Significant concomitant diseases (such as malignant diseases, other neurological or psychiatric disorders, musculoskeletal problems affecting walking, pain, uncorrected visual or hearing impairment) Cognitive impairment as defined by a MoCA cut-off score of 26/30 (<26=impaired cognition) Anxiety or depression as signified by a HADS anxiety Pregnancy Relapse of MS within the last 3 months before the study Any medication initiation or change (including corticosteroids) or any physiotherapy change or inpatient rehabilitation within 3 months prior to the study Any change of symptomatic treatment affecting walking (medication or physiotherapy) or of disease modifying treatment during the study will lead to an exclusion of the participant from further analysis |
| Healthy controls |
Age-matched and gender-matched Without any history of neurological, psychiatric or orthopaedic disorders |
| MRI/fMRI contraindications |
Metallic or electricity conducting implants or prostheses (cardiac pacemaker, insulin pump, middle-ear implants, heart valve or hip prostheses, artificial teeth, hearing aid, etc) in or on the body Non-removable metal parts (coil, braces, etc) or metal shrapnel in or on the body Tattoos in the head or neck area, nicotine plasters or cosmetic eye modifications Pregnancy Epilepsy Claustrophobia |
fMRI, functional MRI; HADS, Hospital and Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment; MS, multiple sclerosis.
Figure 1Key elements of the intervention in the three groups.
Figure 2Content of semi-structured interviews.
Schedule of study procedures
| Study period | Follow-up test | |||||
| Enrolment | Allocation | Postallocation | ||||
| Screening | Baseline test | Postintervention test | Follow-up phone call | |||
| Timepoint | − |
|
|
|
|
|
|
| ||||||
| Eligibility screen | X | |||||
| Informed consent | X | |||||
| Allocation | X | |||||
|
| ||||||
| Music-cued MI group |
| |||||
| Music-cued MI and gait training group |
| |||||
| Music-cued gait training group |
| |||||
|
| ||||||
| Demographics (age, gender) | X | |||||
| Clinical characteristics (EDSS, MS phenotype, disease duration, disease modifying treatment*) | X | |||||
| Global cognitive impairment (MoCA test) | X | X | X | |||
| Anxiety and depression (HADS) | X | X | X | |||
| Suicidality (narrative screening) | X | X | X | |||
|
| ||||||
| Walking speed and distance (T25FW, 2MWT) | X | X | X | |||
|
| ||||||
| Brain activation patterns (fMRI) | X | X | ||||
| MS related fatigue (NFI-MS) | X | X | X | |||
| Health-related QoL (MusiQoL) | X | X | X | |||
| MI ability (KVIQ-10, mental chronometry test) | X | X | X | |||
| Cognitive functioning (SDMT) | X | X | X | |||
| Music-induced motivation in exercise (BMRI-2) | X | X | X | |||
| Music-induced pleasure & arousal (SAM) | X | |||||
| MS specific self-efficacy (USE-MS) | ||||||
| Adverse events and adverse reactions (log) | X | X | X | |||
| Falls (log) | X | X | X | |||
| Acceptability of the intervention, adherence and coping (checklist, weekly semi-structured phone interviews) |
| |||||
| Self-report health status and feedback on the study intervention (follow-up semi-structured phone interviews) | X | |||||
*Three categories of disease modifying treatment (DMT): (1) no DMTs; (2) moderately effective DMTs: interferon-b 1a and 1b, pegylated interferon-b 1a, glatiramer acetate, dimethyl fumarate, teriflunomide, azathioprine, intravenous immunoglobulins; (3) highly effective DMTs: alemtuzumab, cladribine, fingolimod, natalizumab, ocrelizumab, cyclophosphamide, mitoxantrone, rituximab, siponimod, ofatumumab and ozanimod.125
BMRI-2, Brunel Music-Rating Inventory-2; EDSS, Expanded Disability Status Scale; fMRI, functional MRI; HADS, Hospital Anxiety and Depression Scale; KVIQ-10, Kinaesthetic and Visual Imagery Questionnaire, short version; MI, motor imagery; MoCA, Montreal Cognitive Assessment; MS, multiple sclerosis; MusiQoL, Multiple Sclerosis International Quality of Life; 2MWT, 2 min Walk Test; NFI-MS, Neurological Fatigue Index-Multiple Sclerosis; SAM, Self-Assessment Manikin; SDMT, Symbol Digit Modalities Test; T25FW, Timed 25-Foot Walk; USE-MS, Unidimensional Self-Efficacy Scale for Multiple Sclerosis.
Figure 3Schematic representation of the block functional MRI-paradigm.